Author Details

Scroll

Refine your search

Collections

Medical Collection

Co-Authors

Journals

Asian Journal of Pharmaceutical Research and Health Care

Year

Authors

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Truong, Phuong Kim

miRNA-141 as the Biomarker for Human Cancers

Abstract Views :281 | PDF Views:176

Authors

Thuan Duc Lao ¹, Phuong Kim Truong ², Thuy Ai Huyen Le ²

Affiliations
1 University of Science, Vietnam National University, Ho Chi Minh City, VN
2 Department of Pharmaceutical and Medical Biotechnology, Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 2 (2018), Pagination: 42-49

Abstract

microRNA (miRNA) is considered to be a pivotal role in human numerous biological process, and their abnormal expression that functions either as tumor suppressor or oncogenes results in human cancer initiation and development microRNA-141 (miR-141), belonged to the miR-200 family, located at 12p13.31 and is also found to be abundantly expressed in many human cancers. Additionally, Prognostic and predictive miR-141 signatures have been defined for a variety of cancer types. This review summarized the biogenesis and processing of miRNA, as well as the roles of miR-141 in human cancer pathways, its targets and the potential utility of miR-141 as prognostic biomarkers.

Keywords

Biomarker, Human Cancer, microRNA, microRNA-141.

Full Text

References

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6–7. Crossref PMid:16009126

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843–54. Crossref

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509–24. Crossref PMid:25027649

Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9(2):102–14. Crossref PMid:18197166

Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 24(7):e2156. Crossref PMid:27010857 PMCid:PMC4823963

Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175–205. Crossref PMid:17506695

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857–66. Crossref PMid:17060945

Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848–56. Crossref PMid:19884536 PMCid:PMC2793003

Spence T, Bruce J, Yip KW, Liu FF. MicroRNAs in nasopharyngeal carcinoma. Chin Clin Oncol. 2016; 5(2):17. Crossref PMid:27121877

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–97. Crossref

Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 2010; 11(7):537–61. Crossref PMid:21532838 PMCid:PMC3048316

Lin SL, Kim H, Ying SY. Intron-mediated RNA interference and microRNA (miRNA). Front Biosci. 2008; 13:2216–30. Crossref PMid:17981704

Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004; 10(12):1957–66. Crossref PMid:15525708 PMCid:PMC1370684

Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051–60. Crossref PMid:15372072 PMCid:PMC524334

Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126–39. Crossref PMid:19165215

Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415–9. Crossref PMid:14508493

Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes and Development. 2003; 17(24):3011–6. Crossref PMid:14681208 PMCid:PMC305252

Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4):252–63. Crossref PMid:20216554

Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009; 28(3-4):369–78. Crossref PMid:20012925

Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis. 2010; 31(4):559–66. Crossref PMid:20053927

Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014; 9(2):e88393. Crossref PMid:24551096 PMCid:PMC3923786

Wu SM, Ai HW, Zhang DY, Han XQ, Pan Q, Luo FL, et al. MiR-141 targets ZEB2 to suppress HCC progression. Tumour Biol. 2014; 35(10):9993–7. Crossref PMid:25008569

Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang J, et al. microRNA-141 inhibits cell proliferation and invasion and promotes apoptosis by targeting hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC Cancer. 2014; 14:879. Crossref PMid:25425543 PMCid:PMC4289273

Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci. 2010; 55(8):2365–72. Crossref PMid:19830559

Ding L, Yu LL, Han N, Zhang BT. miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4. Oncol Lett. 2017; 13(3):1665–71. Crossref PMid:28454307 PMCid:PMC5403415

Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017; 482(4):1381–6. Crossref PMid:27956179

Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011; 128(3):608–16. Crossref PMid:20473869

Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY, et al. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate. 2012; 72(14):1514–22. Crossref PMid:22314666

Wang XL, Xie HY, Zhu CD, Zhu XF, Cao GX, Chen XH, et al. Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumour Biol. 2015; 36(2):877–83. Crossref PMid:25304156

Mahdavinezhad A, Mousavi-Bahar SH, Poorolajal J, Yadegarazari R, Jafari M, Shabab N, et al. Evaluation of miR141, miR-200c, miR-30b expression and clinicopathological features of bladder cancer. Int J Mol Cell Med. 2015; 4(1):32–9. PMid:25815280 PMCid:PMC4359703

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32(36):4284–93. Crossref PMid:23045278

Chen JL, Chen F, Zhang TT, Liu NF. Suppression of SIK1 by miR-141 in human ovarian cancer cell lines and tissues. Int J Mol Med. 2016; 37(6):1601–10. Crossref PMid:27081781

Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011; 17(12):1627–35. Crossref PMid:22101765

Li P, Xu T, Zhou X, Liao L, Pang G, Luo W, et al. Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: Involvement of ANP32E targeting. Cancer Med. 2017; 6(3):662–72. Crossref PMid:28220627 PMCid:PMC5345683

Choi SK, Kim HS, Jin T, Hwang EH, Jung M, Moon WK. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. BMC Cancer. 2016; 16:570. Crossref PMid:27484639 PMCid:PMC4969651

Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, et al. Progesterone downregulation of miR141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015; 34(28):3676–87. Crossref PMid:25241899 PMCid:PMC4369481

Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell–cell junctions. Nucleic Acids Research. 2005; 33(20):6566–78. Crossref PMid:16314317 PMCid:PMC1298926

Tang K, Xu H. Prognostic value of meta-signature miRNAs in renal cell carcinoma: An integrated miRNA expression profiling analysis. Scientific Reports. 2015; 5:10272. Crossref PMid:25974855 PMCid:PMC4431463

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 2014; 20(10):2617–30. Crossref PMid:24647573

Walworth NC. Cell-cycle checkpoint kinases: Checking in on the cell cycle. Curr Opin Cell Biol. 2000; 12(6):697–704. Crossref

Tricoli JV, Jacobson JW. MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007; 67(10):4553–5. Crossref PMid:17510380

Macha MA, Seshacharyulu P, Krishn SR, Pai P, Rachagani S, Jain M, et al. MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des.2014; 20(33):5287–97. Crossref PMid:24479799 PMCid:PMC4113605

Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016; 13(12):734–52. Crossref PMid:27804986

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654–9. Crossref PMid:17486113

Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biology and Medicine. 2013; 10(3):123–30. PMid:24379986 PMCid:PMC3860338

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513–8. Crossref PMid:18663219 PMCid:PMC2492472

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011; 9(1):39–45. Crossref PMid:21723797

Antolín S, Calvo L, Blanco-Calvo M, Santiago MP, LorenzoPati-o MJ, Haz-Conde M, et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 2015; 15:297. Crossref PMid:25885099 PMCid:PMC4405843

Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011; 6(3):e17745. Crossref PMid:21445232 PMCid:PMC3060165

The Major Molecular Causes of Familial Hypercholesterolemia

Abstract Views :258 | PDF Views:139

Authors

Phuong Kim Truong ¹, Thuan Duc Lao ¹, Thuy Huyen Ai Le ¹

Affiliations
1 Department of Pharmaceutical and Medical Biotechnology, Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 10, No 2 (2018), Pagination: 60-68

Abstract

Familial Hypercholesterolemia (FH) is a common dominant disorder of cholesterol metabolism characterized by elevated serum cholesterol level which results in increasing risk of many diseases. The major cause of FH is the loss-of-function in Low Density Lipoprotein Receptor (LDLR), Apolipoprotein B-100 (ApoB-100), Low Density Lipoprotein Receptor Adapter Protein (LDLRAP1), and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) gene that revealed to the defects in the uptake and degradation of Low Density Lipoprotein (LDL) via the LDLR pathway. In this review, we have highlighted the molecular disorder in LDLR, ApoB-100, LDLRAP1 and PCSK gene, leading to the possible accession on early diagnosis, screening of FH based on the clinical characteristics, family history, evaluated LDL-Cholesterol levels and recently genetic testing aided, hence molecular based therapy will be applied or recommended to FH patients.

Keywords

Apolipoprotein B-100 (ApoB-100), Familial Hypercholesterolemia, Low Density Lipoprotein Receptor, Low Density Lipoprotein Receptor Adapter Protein, Proprotein Convertase Subtilisin/Kexin Type 9.

Full Text

References

Najam O, Ray KK. Familial hypercholesterolemia: A review of the natural history, diagnosis, and management. Cardiol Ther. 2015; 4(1):25–38. Crossref PMid:25769531 PMCid:PMC4472649

Soutar AK, Naoumova RP. Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007; 4(4):214–25. Crossref PMid:17380167

Farrokhi E, Shayesteh F, Asadi Mobarakeh S, Roghani Dehkordi F, Ghatreh Samani K, Hashemzadeh Chaleshtori M. Molecular characterization of Iranian patients with possible familial hypercholesterolemia. Indian J Clin Biochem. 2011; 26(3):244–8. Crossref PMid:22754187 PMCid:PMC3162949

Khachadurian AK. The inheritance of essential Familial Hypercholesterolemia. Am J Med. 1964; 37:402–7. Crossref

Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993; 72(2):171–6. Crossref

Séguro F, Bongard V, Bérard E, Taraszkiewicz D, Ruidavets JB, Ferrières J. Dutch lipid clinic network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population. Arch Cardiovasc Dis. 2015; 108(10):511–8. Crossref PMid:26073227

Goldstein JL, Brown MS. Molecular medicine. The cholesterol quartet. Science. 2001; 292(5520):1310–2. Crossref

Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet. 2008; 73(1):1–13. Crossref PMid:18028451

Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. National lipid association expert panel on familial hypercholesterolemia. Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011(3 Suppl); 5:S9– 17. Crossref PMid:21600530

Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, et al. Familial defective Apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990; 31(8):1337– 49. PMid:2280177

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001; 358(9298):2026–33. Crossref

Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154–6. Crossref PMid:12730697

13. Banaszak LJ, Ranatunga WK. The assembly of apoBcontaining lipoproteins: A structural biology point of view. Ann Med. 2008; 40(4):253–67. Crossref PMid:18428019

Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res. 2009; 50(Suppl):S172–7. Crossref PMid:19020338 PMCid:PMC2674748

Brown MS, Goldstein JL. Familial hypercholesterolemia: Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci U S A. 1974; 71(3):788–92. Crossref

Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci U S A. 1984; 81(9):2826– 30. Crossref PMid:6326146 PMCid:PMC345163

Lindgren V, Luskey KL, Russell DW, Francke U. Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci U S A. 1985; 82(24):8567– 71. Crossref PMid:3866240 PMCid:PMC390958

Usifo E, Leigh SE, Whittall RA, Lench N, Taylor A, Yeats C, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet. 2012; 76(5):387–401. Crossref PMid:22881376

Arráiz N, Bermúdez V, Rondon N, Reyes F, Borjas L, Solís E, et al. Novel mutations identification in exon 4 of LDLR gene in patients with moderate hypercholesterolemia in a Venezuelan population. Am J Ther. 2010; 17(3):325–9. Crossref PMid:20019594

Neff D, Ruschitzka F, Hersberger M, Enseleit F, Hürlimann D, Noll G, et al. Detection of a novel exon 4 low-density lipoprotein receptor gene deletion in a swiss family with severe familial hypercholesterolemia. Clin Chem Lab Med. 2003; 41(3):266–71. Crossref PMid:12705331

Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990; 24:133–70. Crossref PMid:2088165

Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992; 1:445–66. Crossref PMid:1301956

Varghese MJ. Familial hypercholesterolemia: A review. Annals of Pediatric Cardiology. 2014; 7(2):107–17. Crossref PMid:24987256 PMCid:PMC4070199

Knott TJ, Rall SC Jr, Innerarity TL, Jacobson SF, Urdea MS, Levy-Wilson B, et al. Human apolipoprotein B: Structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization. Science. 1985; 230(4721):37– 43. Crossref PMid:2994225

Law SW, Lackner KJ, Hospattankar AV, Anchors JM, Sakaguchi AY, Naylor SL, et al. Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. Proc Natl Acad Sci U S A. 1985; 82(24):8340–4. Crossref PMid:3001697 PMCid:PMC390911

Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, Mc Carthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A. 1989; 86(2):587–91. Crossref PMid:2563166 PMCid:PMC286517

Dunning AM, Houlston R, Frostegård J, Revill J, Nilsson J, Hamsten A, et al. Genetic evidence that the putative receptor binding domain of apolipoprotein B (residues 3130 to 3630) is not the only region of the protein involved in interaction with the low density lipoprotein receptor. Biochim Biophys Acta. 1991; 1096(3):231–7. Crossref

Gaffney D, Reid JM, Cameron IM, Vass K, Caslake MJ, Shepherd J, et al. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol. 1995; 15(8):1025–9. Crossref PMid:7627691

Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest. 1995; 95(3):1225–34. Crossref PMid:7883971 PMCid:PMC441461

Borén J, Ekström U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem. 2001; 276(12):9214–8. Crossref PMid:11115503

Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001; 292(5520):1394–8. Crossref PMid:11326085

Sun XM, Patel DD, Acosta JC, Gil J, Soutar AK. Premature senescence in cells from patients with Autosomal Recessive Hypercholesterolemia (ARH): Evidence for a role for ARH in mitosis. Arterioscler ThrombVasc Biol. 2011; 31(10):2270–7. Crossref PMid:21778424

Soutar AK, Naoumova RP. Autosomal Recessive Hypercholesterolemia. Semin Vasc Med. 2004; 4(3):241–8. Crossref PMid:15630633

Tada H, Kawashiri MA, Ohtani R, Noguchi T, Nakanishi C, Konno T, et al. A novel type of familial hypercholesterolemia: Double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis. 2011; 219(2):663–6. Crossref PMid:21872251

Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007; 32(2):71–7. Crossref PMid:17215125 PMCid:PMC2711871

Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008; 49(6):1152–6. Crossref PMid:18375913 PMCid:PMC2386899

Hartgers ML, Ray KK, Hovingh GK. New approaches in detection and treatment of familial hypercholesterolemia. Curr Cardiol Rep. 2015; 17(12):109. Crossref PMid:26482752 PMCid:PMC4611021

Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001; 5(4):378–87. Crossref PMid:12067471

Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010; 86(5):484–93. Crossref PMid:20467214 PMCid:PMC3108295

Wong E, Goldberg T. Mipomersen (kynamro): A novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P T. 2014; 39(2):119–22.

Agarwala A, Jones P, Nambi V. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations. Curr Atheroscler Rep. 2015; 17(1):467. Crossref PMid:25398643

Jamil H, Dickson JK Jr, Chu CH, Lago MW, Rinehart JK, Biller SA, et al. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J Biol Chem. 1995; 270(12):6549–54. Crossref PMid:7896791

Davis KA, Miyares MA. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health Syst Pharm. 2014; 71(12):1001–8. Crossref PMid:24865757

Zimmerman MP. How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control? American Health and Drug Benefits. 2015; 8(8):436–42. PMid:26702335 PMCid:PMC4684634

Paton DM. PCSK9 inhibitors: Monoclonal antibodies for the treatment of hypercholesterolemia. Drugs Today (Barc). 2016; 52(3):183–92. Crossref PMid:27186592

Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol.2017; 9(2):76–91. Crossref PMid:28289523 PMCid:PMC5329749

Burke AC, Dron JS, Hegele RA, Huff MW. PCSK9: Regulation and target for drug development for dyslipidemia. Annu Rev Pharmacol Toxico. 2017; 57:223–44. Crossref PMid:27575716

The Prognosis Value of CDH-1 Methylation-The Epigenetic Biomarker in Nasopharyngeal Carcinoma:Systematic Review and Meta-Analysis

Abstract Views :188 | PDF Views:168

Authors

Thuan Duc Lao ¹, Phuong Kim Truong ¹, Hue Hong Thieu ², Thuy Ai Huyen Le ¹

Affiliations
1 Faculty of Biotechnology, Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City − 700000, VN
2 Faculty of Biology and Biotechnology, Ho Chi Minh City University of Science, Hồ Chí Minh − 700000, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 11, No 2-4 (2019), Pagination: 68-74

Abstract

Background: The phenome of CDH-1 gene methylation has been reported to be associated with the nasopharyngeal tumorigenesis. Objective: Aiming to evaluate the association between the CDH-1 gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for nasopharyngeal cancer risk based on meta-analysis. Materials and Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds Ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Results: Total of 12 studies, including 500 samples from NPC patients and 201 samples from non-cancerous samples, were enrolled in current study. Overall, the frequency of CDH-1 gene methylation were 48.50% and 3.09% in the case and control group, respectively. The association between the CDH-1 gene methylation and risk of NPC was also confirmed by calculating OR value of 15.33 (95% CI = 7.82-30.06), based on the fix-effects model. Additionally, the significant association was also found between the methylation of CDH-1 gene and subgroups. Conclusion: this meta-analysis provides scientific evidences to suggest the CDH-1 methylation was the potential biomarker for risk of NPC.

Keywords

CDH-1, Epigenetic Biomarker, Nasopharyngeal carcinoma, Meta-Analysis.

Full Text

References

Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet 1990; 335(8686):371-74. https://doi.org/10.1016/01406736(90)90206-K

Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Res. 2009; 143(2):209-21. https://doi.org/10.1016/j.virusres.2009.07.005. PMid: 19596032, PMCid: PMC2731007.

Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and inequality in the incidence and mortality of Nasopharynx Cancer in Asia. Osong. Public Health Res. Perspect. 2016; 7(6):360-72. https:// doi.org/10.1016/j.phrp.2016.11.002. PMid: 28053841, PMCid: PMC5194228.

Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH, Le THA. miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz. Oral. Res. 2018a; 32:e126. https://doi.org/10.1590/1807-3107bor-2018.vol32.0126. PMid: 30569973.

Lao TD, Nguyen DH, Le THA. Study of mir-141 and its potential targeted mRNA PTEN expression in Nasopharyngeal Carcinoma: From in Silico to initial experiment analysis. AJPRHC. 2018b; 10(3):66-74. https://doi.org/10.18311/ajprhc/2018/22341.

Lao TD, Le THA. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: An update report. Adv. Life Sci. 2020; 7(2):86-90.

Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: An Overview. Cell Physiol. Biochem. 2018; 51(6):2647-93. https://doi.org/10.1159/000495956. PMid: 30562755.

Goodwin M, Yap AS. Classical cadherin adhesion molecules: Coordinating cell adhesion, signaling and the cytoskeleton. J. Mol. Histol. 2004; 35:839-44. https://doi.org/10.1007/s10735004-1833-2. PMid: 15609097.

Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27(55):6920-29. https://doi.org/10.1038/ onc.2008.343. PMid: 19029934, PMCid: PMC2745643.

Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097. PMid: 19621072, PMCid: PMC2707599.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21(11):1539-58. https://doi.org/10.1002/sim.1186. PMid: 12111919.

DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat. Med. 1996; 15(12):1237-48. https://doi.org/10.1002/(SICI)1097-0258(19960630)15:12<1237::AIDSIM301> 3.0.CO;2-N.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60.https://doi.org/10.1136/bmj.327.7414.557 PMid: 12958120, PMCid: PMC192859.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088101. https://doi.org/10.2307/2533446. PMid: 7786990.

Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629. PMid: 9310563, PMCid: PMC2127453.

Chang HW, Chan A, Kwong DLW, Wei WI, Sham JST, Yuen APW. Evaluation of Hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int. J. Cancer. 2003; 105:851-55. https://doi.org/10.1002/ijc.11162. PMid: 12767073.

Wong TS, Tang KC, Kwong DLW, Sham JST, Wei WI, Kwong YL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. International Journal of Oncology. 2003; 22:869-74. https://doi.org/10.3892/ijo.22.4.869.

Tsao SW, Liu Y, Wang XX, Yuen PW, Leung SY, Yuen ST, et al. The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. European Journal of Cancer. 2003; 39:524-31. https://doi.org/10.1016/S0959-8049(02)00494-X.

Li Z, Lin SX, Liang YJ. Influence of E-cadherin promoter methylation and mutation of beta-catenin on invasion and metastasis of nasopharyngeal carcinoma cells. Europe PMC. 2003; 25(3):238-42.

Li Z, Lin S, Liang YJ. Detection of gene promoter methylation and mRNA, protein expression levels of E-cadherin in nasopharyngeal carcinoma. Springer. 2003; 32(1):25.30. PMID:12760799

Wong TS, Kwong DLW, Sham JST, Wei WI, Kwong YL, Yuen APW. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clinical Cancer Research. 2004; 10:2401-06. https://doi.org/10.1158/10780432.CCR-03-0139. PMid: 15073117.

Li Z, Ren Y, Lin SX, Liang YJ, Liang HZ. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma. Europe PMC. 2004; 117(8):1232-39.

Tan SH, Ida H, Goh BC, Hsieh W, Loh M, Ito Y. Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Research. 2006; 26:4287-92.

Niemhom S, Kitazawa S, Kitazawa R, Maeda S, Leopairat J. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detection and Prevention. 2008; 32:127-34. https://doi.org/10.1016/j.cdp.2008.05.005. PMid:18632221.

Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-Cadherin gene promoters in nasopharyngeal carcinoma biopsies from tunisian patients. Anticancer Research. 2008; 28:2161-68.

Ran Y, Wu S, You Y. Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J. Biochem. 2011; 149(1):49-54. https://doi.org/10.1093/jb/mvq128.PMid: 21059597.

Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clinica. Chimica. Acta. 2012; 413:795-802. https://doi.org/10.1016/j.cca.2012.01.018. PMid: 22296674.

Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin. J. Cancer. 2011; 30(4):231-39. https://doi.org/10.5732/cjc.011.10080 PMid: 21439244, PMCid: PMC4013349.

Jiang W, Cai R, Chen QQ. DNA Methylation biomarkers for nasopharyngeal carcinoma: Diagnostic and prognostic tools. Asian Pac. J. Cancer Prev. 2015; 16(18):8059-65. https://doi.org/10.7314/APJCP.2015.16.18.8059. PMid: 26745039.

Semb H, Christofori G. The tumor-suppressor functions of E-cadherin. Am. J. Hum. Genet. 1998; 63(6):1588-93. https://doi.org/10.1086/302173. PMid: 9837810, PMCid: PMC1377629.

Pećina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003; 3(1):17. https://doi.org/10.1186/1475-2867-3-17 PMid: 14613514, PMCid: PMC270068.

Huang Z, Bassil CF, Murphy SK. Methylation-specific PCR. Methods Mol. Biol. 2013; 1049:75-82. https://doi.org/10.1007/978-1-62703-547-7_7. PMid: 23913210.

Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M. DAPK1 promoter Methylation and cervical cancer risk: A systematic review and a meta-analysis. PLoS One. 2015; 10(8):e0135078. https:// doi.org/10.1371/journal.pone.0135078. PMid: 26267895, PMCid: PMC4534406.

Epidemiology, Incidence, Mortality of Cervical Cancer in Southeast Asia and their Relationship: An Update Report

Abstract Views :253 | PDF Views:133

Authors

Nam Hoang Dang Phan ¹, Tung Thanh Nguyen ¹, Nhan Thanh Vo ¹, Trinh Tuyet Thi Le ¹, Tran Bao Hoang Tran ¹, Phuong Kim Truong ¹, Thuy Ai Huyen Le ¹, Thuan Duc Lao ¹

Affiliations
1 Department of Pharmaceutical and Medical Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, VN

Source

Asian Journal of Pharmaceutical Research and Health Care, Vol 12, No 3 (2020), Pagination: 97-101

Abstract

Cervical cancer is the leading-caused cancer death in women worldwide, especially occurring in the developing countries. The understanding of the incidence, mortality, and their relationship with the Human Development Index (HDI) and its three dimensions, including gross national income per capita, education index, and life expectancy, is crucial to establish the best way to prevent the increasing of cervical cancer in future. The data of the incidence (-ASR), mortality (-ASR), HDI were extracted from the GLOBOCAN and Human Development Reports database. Person Correlation Coefficient was applied to characterize the relationship among them. The incidence and mortality of Cervical Cancer in Southeast Asia (total new cases: 62,456 cases, counting for 19, 81%; new death cases: 35,738, counting for 21.22%), ranked in the top three of Asian regions. There was the negative correlation between the incidence-ASR, mortality-ASR with HDI, and its three dimensions. A significant correlation between the mortality-ASR rate of cervical cancer and Life expectancy at birth was recorded. The cancer of cervix gravitates to Asian region, including Southeast Asian countries. There was a significant relationship between the mortality-ASR rate of cervical cancer and Life expectancy at birth.

Keywords

Cervical Cancer, Incidence, Mortality, Southeast Asia.

Full Text

References

Sherris J, Herdman C, Elias C. Cervical cancer in the developing world. West J. Med. 2001; 175(4):231-33. https://doi.org/10.1136/ewjm.175.4.231. PMid: 11577044, PMCid: PMC1071564.

Wong LP. Knowledge and attitudes about HPV infection, HPV vaccination, and cervical cancer among rural Southeast Asian Women. Int. J. Behav. Med. 2011; 18(2):105-11. https://doi.org/10.1007/s12529-010-9104-y. PMid: 20524163.

Mohanty G, Ghosh SN. Risk factors for cancer of cervix, status of screening and methods for its detection. Arch. Gynecol. Obstet. 2015; 291(2):247-49. https://doi.org/10.1007/s00404-014-3492-1. PMid:25273981.

Muñoz N, Bosch FX, De Sanjosé S, et al. Epidemiologic classification of human Papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003; 348(6):518-27. https://doi.org/10.1056/NEJMoa021641. PMid: 12571259.

Lao D, Le H. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: An update report. Adv. Life Sci. 2020; 7(2):86-90.

Bray F, Jemal A, Grey N, Ferlay J., Forman, D. Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. Lancet Oncol. 2012; 13(8):790-01. https://doi.org/10.1016/S14702045(12)70211-5.

Soheylizad M, Khazaei S, Jenabi E, Delpisheh A, Veisani Y. The relationship between human development index and its components with thyroid cancer incidence and mortality: Using the decomposition approach. Int. J. Endocrinol. Metab. 2018; 16(4):e65078. https://doi.org/10.5812/ijem.65078. PMid: 30464773, PMCid: PMC6218660.

Mahdavifar N, Towhidi F, Makhsosi BR, et al. Incidence and mortality of Nasopharynx cancer and its relationship with human development index in the world in 2012. World J. Oncol. 2016; 7(5-6):109-18. https://doi.org/10.14740/wjon980w. PMid:28983375 PMCid:PMC5624652.

Cancer Today. Cancer Fact sheet. Accessed 12th December, 2019. Available from https://gco.iarc.fr/today/fact-sheetscancers.

United Nations Development Programme. Human Development Data (1990-2018). Accessed 12th December 2019. Available from http://hdr.undp.org/en/data.

Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Heal, 2020; 8(2):e191-03. https://doi.org/10.1016/S2214-109X(19)30482-6.

Momenimovahed Z, Salehiniya H. Incidence, mortality and risk factors of cervical cancer in the world. Biomed. Res. Ther. 2017; 4(12):1795-811. https://doi.org/10.15419/bmrat.v4i12.386.

Username
Password
Remember me